Featured Research

from universities, journals, and other organizations

Rx For Contact Lenses: Mobility + Lubricity = Comfort And Safety

Date:
May 8, 2001
Source:
American Chemical Society
Summary:
Freedom to move around is a great thing. Just ask a group of researchers who have created a model they hope will lead to better contact lenses. In their eyes, greater lens mobility is needed to improve the safety of extended wear soft lenses.

Freedom to move around is a great thing. Just ask a group of researchers who have created a model they hope will lead to better contact lenses. In their eyes, greater lens mobility is needed to improve the safety of extended wear soft lenses.

Their findings are presented in the July issue of Industrial & Engineering Chemistry Research, a peer-reviewed journal of the American Chemical Society, the world's largest scientific society. The study was led by Clayton Radke, Ph.D., at the University of California, Berkeley.

Researchers and lens manufacturers have known that soft lenses need to be able to move when the eye blinks in order to extend the length of time a lens may be worn safely. Up-and-down lens movement is bothersome, Radke says. Lenses that allow a greater degree of in-and-out, or squeezing, motion work better. The in-and-out motion is less noticeable and permits higher levels of lubricity, helping to flush out impurities that can cause eye problems, according to Radke.

Contact lenses for use up to 30 days without removal were approved by the U.S. Food and Drug Administration in 1981. But increased eye infections and other problems led the FDA to revise its recommendation downward to seven days. Design and material improvements could lengthen that period, Radke said.

Researchers focused on the thin layer of moisture between the lens and the eye known as the "posterior lens tear film." Less than a tenth as thick as a human hair, it can trap bacteria, debris and other irritants, causing problems ranging from bloodshot eyes to conjunctivitis, according to Radke.

He said a lens with greater mobility could result in fewer problems. Soft contact lenses currently in use move very little -- typically less than a tenth of a millimeter per blink, he added.

Radke compared a previously published 23-person clinical experiment involving soft lens wearers with his computer models to gauge the performance of the posterior lens tear film. He found that the tear film liquid under a soft contact lens is typically flushed in about 30 minutes, while bacteria and inflammatory debris take a bit longer. Unfortunately, however, even half an hour may be too long for such material to remain in the eye, he said.

Accordingly, new lens designs are needed, he said. "This study is important to understanding the origin of adverse responses some people have with wearing soft contact lenses and to seeking better lens designs to alleviate them. However, there is always a compromise between increased lens motion and comfort."

For this reason, more study is needed to find the range of motion people can tolerate and to design new lenses that can improve the flushing of eye contaminants, he added.

Of the nearly 25 million Americans who wear contact lenses, approximately 80 percent wear soft lenses, according to the American Optometric Association. That percentage includes daily wear, extended wear and disposable contacts.

Most disposable contacts use the same materials as daily wear soft contact lenses. As a result, they also are vulnerable to irritant problems. Newly introduced silicone hydrogel soft contact lenses provide improved oxygen transfer through the lens to the eye but do not eliminate all adverse responses in extended wear, Radke said. An exception is hard (rigid, gas permeable) lenses, which can move up and down by several millimeters per blink and clear the eye of irritants quicker because of their smaller diameter. Their greater movement and smaller size, however, mean hard contact lenses tend to be more uncomfortable and less popular.

The research cited above was partially funded by Bausch and Lomb and Ciba-Vision Corporation.


Story Source:

The above story is based on materials provided by American Chemical Society. Note: Materials may be edited for content and length.


Cite This Page:

American Chemical Society. "Rx For Contact Lenses: Mobility + Lubricity = Comfort And Safety." ScienceDaily. ScienceDaily, 8 May 2001. <www.sciencedaily.com/releases/2001/05/010508082512.htm>.
American Chemical Society. (2001, May 8). Rx For Contact Lenses: Mobility + Lubricity = Comfort And Safety. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2001/05/010508082512.htm
American Chemical Society. "Rx For Contact Lenses: Mobility + Lubricity = Comfort And Safety." ScienceDaily. www.sciencedaily.com/releases/2001/05/010508082512.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins